Excellent (90 to 100%)
See Additional Information

Spectrum of Activity


General Information

  • Aspergillosis.
  • Candida infections both mucocutaneous and invasive - i.e. Candidemia.
  • Antifungal prophylaxis in immunocompromised patients.
  • Therapeutic drug monitoring may be helpful to ensure adequate concentrations and exclude toxicity (Discuss with ID).
  • QTc interval in patients at elevated risk.
  • Monitor hepatic profile.
  • Drug interactions
  • GI upset
  • QTc prolongation
  • Hepatic enzyme abnormalities
  • Rash - up to 20%
  • Visual disturbance (reversible)
  • Peripheral neuropathy
  • Fluorosis

CYP450 interactions ++.

Other QTc prolonging agents.

Recommend review of patient medications due to high frequency of significant interactions.

Give 1 hour pre or post meals (as food may decrease voriconazole absorption).

(Absorption is independent of gastric pH)

Restricted to Infectious Diseases (ID)/Antimicrobial Stewardship Program (ASP) and Oncology.


  • PO: $3.33/Dose; $33.30/5 Days
  • IV: $30.61/Dose; $306.10/5 Days

Antimicrobial class: Triazole antifungal, Second generation

Pregnancy category: D

Urine penetration: Poor

Lung penetration: Therapeutic

CSF penetration: Therapeutic